Quick Answer
Corvus Pharmaceuticals, Inc. reported Cash and Equivalents of $4.58 million for fiscal year 2025.
Corvus Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $4.58M | -47.6% |
| 2024 | $8.74M | -30.7% |
| 2023 | $12.62M | -4.1% |
| 2022 | $13.16M | -79.3% |
| 2021 | $63.46M | +285.6% |
| 2020 | $16.45M | +219.3% |
| 2019 | $5.15M | -86.9% |
| 2018 | $39.20M | -13.1% |
| 2017 | $45.11M | +793.2% |
| 2016 | $5.05M | +23.0% |
| 2015 | $4.11M | -67.2% |
| 2014 | $12.52M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.87M | -38.7% | -80.5% |
| June 30, 2025 | $14.69M | -1.0% | +193.9% |
| March 31, 2025 | $5.00M | -33.0% | -42.8% |
| December 31, 2024 | $8.74M | -30.7% | +86.8% |
| September 30, 2024 | $4.68M | -76.7% | -68.5% |
| June 30, 2024 | $14.84M | +93.8% | +99.0% |
| March 31, 2024 | $7.46M | -22.8% | -40.9% |
| December 31, 2023 | $12.62M | -4.1% | -37.2% |
- Corvus Pharmaceuticals, Inc. showed a decrease of -47.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2014–2025 period, Corvus Pharmaceuticals, Inc.’s cash and equivalents has declined by 63.4% (from $12.52 million to $4.58 million).
- The most recent figure is from Corvus Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: